A phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf

بواسطة Chalmers, James D., Gupta, Abhya, Chotirmall, Sanjay Haresh, Armstrong, April, Eickholz, Peter, Hasegawa, Naoki, McShane, Pamela J., O'Donnell, Anne E., Shteinberg, Michal, Watz, Henrik, Eleftheraki, Anastasia, Diefenbach, Claudia, Sauter, Wiebke
منشور في 2024